Andrew Colin, MD

Professor Dr. Andrew R. Colin, MD, serves as a Professor of Pediatrics. Prof. Dr. Colin serves as Director of the Division of Pediatric Pulmonology at Miller School of Medicine, University of Miami. He served as Associate-Chief of a Technion-affiliated Department of Pediatrics in Haifa, Israel. In 1990 he joined the Faculty of Children`s Hospital Boston at Harvard Medical School. He served as Clinical Director of the Division of Respiratory Diseases and also served as Associate Professor at Harvard Medical School. He also served at Children`s Hospital, Boston. He serves as a Member of Medical Advisory Board of EarlySense Ltd. He serves as Member of Scientific Advisory Board at Beyond Air Inc. His expertise includes: asthma, cystic fibrosis, structural and functional development of the respiratory system and related problems including lung diseases of prematurity, pediatric bronchoscopy and more. He participated in research and teaching and received the Klaus Peter International Teaching Award of Harvard Medical School and was the first recipient of the Andrew A. Colin Teaching Award. He is certified by the American Board of Pediatrics in Pediatrics and Pediatric Pulmonology. He has participated in over 20 studies in his field including ones sponsored by the NIH, Genentech, GlaxoSmithKline and the Cystic Fibrosis Foundation’s Therapeutic Development Network. He has authored or co-authored over 80 peer-reviewed publications, as well as multiple reviews. He received his MD at Technion – Israel Institute of Technology and completed his pediatric training in hospitals related to that medical school. He trained in Pediatric Pulmonology and Pediatric Intensive Care at Hadassah Hospital in Jerusalem and subsequently at Children`s Hospital Boston, Harvard Medical School.

Richard Malley, MD

Dr. Richard Malley, also known as Rick, MD serves as an Assistant Professor of Pediatrics of Children’s Hospital Boston. Dr. Malley is an Expert in infectious diseases in children and an experienced Pneumococcal Researcher at Harvard Medical School. He is Affinivax scientific founder and Chairman in Pediatric Infectious Diseases, Boston Children’s Hospital at Kenneth McIntosh. He is an experienced physician with more than 20 years of experience treating infectious diseases, Dr. Malley has led an international effort in the development of novel vaccines in collaboration with colleagues and global nonprofit health organizations such as PATH and the Bill and Melinda Gates Foundation. He serves as a Member of Scientific Advisory Board at Arsanis Inc. He serves as a Director of the Travel and Geographic Medicine Clinic at Boston Children’s Hospital. He serves as a Director of Affinivax, Inc. Dr. Malley serves as a Member of Scientific Advisory Board of Genocea Biosciences, Inc. and Beyond Air Inc. Dr. Malley runs a research laboratory at Children’s Hospital Boston, with funding from NIH and PATH, as well as from the Pamela and Jack Egan Fund. He has initiated a collaboration with Instituto Butantan in Brazil for the manufacture of a pneumococcal vaccine for use in developing countries. He has published over forty peer-reviewed research articles in the field of infectious diseases and vaccines. Dr. Malley authored and co-authored 80 scientific publications in the field of infectious diseases.

Hannah Blau, MD

Professor Dr. Hannah Blau, MD, serves as Member of Scientific Advisory Board at Beyond Air Inc. Prof. Dr. Blau is the Director of the Pulmonology Institute and the Kathy and Lee Graub Cystic Fibrosis Center at Schneider Children’s Medical Center of Israel. Her fields of research include CF, asthma, lung cell biology and inflammation. In particular, recent work has focused on induced sputum in the very young for early markers of inflammation and infection; emerging infections in CF, spectrum of CF phenotypes, preschool pulmonary function testing. She is a founding member (now Secretary) of the Israeli Society for Cystic Fibrosis and was a founding member of the Israel Society for Pediatric Pulmonology. She is a member of the International Pediatric Pulmonary Network of the American Thoracic Society, has been on the Program Committee for the ATS conference through the Pediatric Assembly and is a member of the Pediatric Infection and Immunology Committee of the European Respiratory Society Pediatric Assembly. The Graub CF Centre, which she heads, is part of the Clinical Trials Network (CTN) of the European CF Society (ECFS). She is a member of the Newborn Screening Working Group of the European Cystic Fibrosis Society as well as the author of the Standards of Practice for Sputum Induction as part of the ECFS. She is a reviewer for eight international medical journals and is an author or co-author of 85 peer-reviewed manuscripts.

David Greenberg, MD

Professor Greenberg has almost 20 years of professional experience in the research and treatment of infectious diseases. Since 2005, he has served as a professor of pediatrics and infectious diseases and the principal consultant to the Infectious Disease Clinical Service (pediatric oncology), Chairman of the Division of Pediatrics at Soroka Medical Center in Beer-Sheba, Israel. In June 2014, he was appointed director of Pediatric Infectious Disease Unit at Soroka University Medical Center. In addition, he was a member of the WHO’s Pneumonia Vaccine Trial Investigators’ Group and is a board member of the Educational Committee of the European Society of Pediatric Infectious Diseases. Prof. Greenberg is board certified in pediatrics and has obtained his MD from Ben-Gurion University of the Negev. He completed a fellowship in 1999 in pediatric infectious diseases at British Columbia Children’s Hospital in Vancouver, British Columbia, Canada.

Professor Yossef Av-Gay, PhD

Professor Yossef Av-Gay, Ph.D., co-founded Beyond Air in 2011 and became a director of Beyond Air at that time. Prof. Av-Gay became Beyond Air’s Chief Scientific Officer in 2012 and was Beyond Air’s Chairman from January 2014 until July 2015. He has been a professor of microbiology at the UBC, Faculty of Medicine and the Division of Infection, and is a member of the scientific review panels of the Canadian Institute of Health Research (since 2010), the French Agence Nationale de la Rechereche (since 2008), Innovative Medicine Innovations, the U.S. Natius Diseases since 1997. He is engaged in basic research in microbial genetics and biochemistry of microorganisms, and his research focuses on translational research of bacterial pathogens aiming at antimicrobial drug development. He is a consultant to several pharmaceutical and biotechnology companies, oral Institutes of Health (since 2010), the European Commission FP6, FP7 (since 2002) and Horizon 2020 (since 2014). Dr. Av-Gay received a bachelor’s of science in Biology, a master’s of science in Microbiology and a Ph.D. in Molecular Microbiology from Tel Aviv University.

Stacey Martiniano, M.D.

Stacey Martiniano, M.D., is an Associate Professor of Pediatrics at the University of Colorado and Children’s Hospital Colorado and an Affiliate of National Jewish Health. She is a pediatric pulmonologist who focuses on lung infections, specifically, nontuberculous mycobacterial infections in children with cystic fibrosis. As a national clinical expert and lead researcher, Dr. Martiniano serves as national principal investigator of two multicenter studies in NTM: The Prospective Evaluation of NTM Disease in Cystic Fibrosis (PREDICT Study) and The Prospective Algorithm for Treatment of NTM in Cystic Fibrosis (PATIENCE Study). Both are funded by the Cystic Fibrosis Foundation. She is also the co-investigator and director of the Clinical Research Core for the Cystic Fibrosis Foundation Colorado’s CF NTM Research Development Program.